Abstract
The binding of amyloid beta peptides (Aβ) to plasma membranes appears to be a promising point of intervention in the events leading to the development of Alzheimers disease (AD). This binding has been studied as regards the direct toxicity of Aβ on neurons, and the activation of a local inflammation phase involving microglia. By virtue of its structure, Aβ is able to bind to a variety of biomolecules, including lipids, proteoglycans and proteins. This review focuses on the membrane proteins that can mediate the interaction between Aβ and the plasma membranes in AD. On neurons, these are APP (amyloid precursor protein), the NMDA-R (Nmethyl- D-aspartate receptor), integrins, the β7nicotinic acetylcholine receptor (α7nAChR), the P75 neurotrophin receptor (P75NTR) and the CLAC-P / collagen type XXV (collagen-like Alzheimer amyloid plaque component precursor / collagen XXV). On glial cells, FPRL1 (formyl peptide receptor-like 1), the scavenger receptors A, BI (SR-A, SR-BI) and CD36, a complex involving CD36, α6β1-integrin and CD47, and heparan sulfate proteoglycans have been reported to bind Aβ. It should be noted that integrins, RAGE (receptor for advanced glycosylation endproducts), the Serpin-enzyme complex receptor (SEC-R) and the insulin receptor can bind Aβ and are present on neurons and on glial cells. After a presentation of the structure and the function of each of these proteins, the method used to prove their binding to Aβ is described, and the implication of this binding in AD is discussed. Finally, it is underlined that multireceptor complexes containing integrins may be involved in this interaction.
Keywords: Amyloid-beta, Alzheimer disease, membrane proteins, APP, NMDA receptor, a7nicotinic, acetylcholine receptor, scavenger receptors, integrins
Current Protein & Peptide Science
Title: Binding Sites of Amyloid β-Peptide in Cell Plasma Membrane and Implications for Alzheimers Disease
Volume: 5 Issue: 1
Author(s): Yann Verdier and Botond Penke
Affiliation:
Keywords: Amyloid-beta, Alzheimer disease, membrane proteins, APP, NMDA receptor, a7nicotinic, acetylcholine receptor, scavenger receptors, integrins
Abstract: The binding of amyloid beta peptides (Aβ) to plasma membranes appears to be a promising point of intervention in the events leading to the development of Alzheimers disease (AD). This binding has been studied as regards the direct toxicity of Aβ on neurons, and the activation of a local inflammation phase involving microglia. By virtue of its structure, Aβ is able to bind to a variety of biomolecules, including lipids, proteoglycans and proteins. This review focuses on the membrane proteins that can mediate the interaction between Aβ and the plasma membranes in AD. On neurons, these are APP (amyloid precursor protein), the NMDA-R (Nmethyl- D-aspartate receptor), integrins, the β7nicotinic acetylcholine receptor (α7nAChR), the P75 neurotrophin receptor (P75NTR) and the CLAC-P / collagen type XXV (collagen-like Alzheimer amyloid plaque component precursor / collagen XXV). On glial cells, FPRL1 (formyl peptide receptor-like 1), the scavenger receptors A, BI (SR-A, SR-BI) and CD36, a complex involving CD36, α6β1-integrin and CD47, and heparan sulfate proteoglycans have been reported to bind Aβ. It should be noted that integrins, RAGE (receptor for advanced glycosylation endproducts), the Serpin-enzyme complex receptor (SEC-R) and the insulin receptor can bind Aβ and are present on neurons and on glial cells. After a presentation of the structure and the function of each of these proteins, the method used to prove their binding to Aβ is described, and the implication of this binding in AD is discussed. Finally, it is underlined that multireceptor complexes containing integrins may be involved in this interaction.
Export Options
About this article
Cite this article as:
Verdier Yann and Penke Botond, Binding Sites of Amyloid β-Peptide in Cell Plasma Membrane and Implications for Alzheimers Disease, Current Protein & Peptide Science 2004; 5 (1) . https://dx.doi.org/10.2174/1389203043486937
DOI https://dx.doi.org/10.2174/1389203043486937 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Patents in Cancer Stem Cells
Recent Patents on Biomarkers Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Current Alzheimer Research Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Reviews on Recent Clinical Trials Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7- Trimethylxanthine Hydrazones with In-vitro Neuroprotective and MAO-B Inhibitory Activities
Medicinal Chemistry Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma
Current Bioinformatics Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy